Abstract: A 1.alpha.,24-(OH).sub.2 --V.D.sub.3 cream composition comprising(a) a therapeutically effective amount of 1.alpha.,24-(OH).sub.2 --V.D.sub.3,(b) an oil phase component including(i) a solid oil component composed of 5 to 20 parts by weight of white petrolatum and 5 to 15 parts by weight of higher alcohols and(ii) a liquid oil component comprising of 3 to 10 parts by weight of squalane,(c) an aqueous phase component, and(d) 2.5 to 7.5 parts by weight at least two surfactants, wherein the 1.alpha.,24-(OH).sub.2 --V.D.sub.3 cream composition has a weight ratio of the solid oil component to the liquid oil component (i.e., solid oil component/liquid oil component) of at least approximately 2, the higher alcohols are composed of stearyl alcohol and cetyl alcohol, the weight ratio of the stearyl alcohol to the higher alcohols (i.e., stearyl alcohol/higher alcohols) is approximately 0.65 to approximately 0.

Abstract: An aqueous preparation of active form of vitamin D.sub.3 which is solubilized with a nonionic surface active agent and stabilized with a combination of a specific chelating agent such as citric acid with an antioxidant. Stabilized oral and parenteral preparations of active form of vitamin D.sub.3 can be provided.

Abstract: A sustained release preparation comprising:(a) chitin, chitosan, or a mixture thereof(b) anionic polymer compounds such as those having a carboxyl group, a sulfonic acid group, or a group capable of providing the same, and(c) pharmaceutically active agents.This sustained release preparation can provide the desired sustained-release or dissolution of the pharmaceutically active agents in human organs irrespective of the acidity (i.e., pH conditions) therein.

Abstract: A pharmaceutical composition for external use with the enhanced penetration of a pharmacologically active agent through the skin or mucosa of a warm-blooded animal, said composition comprising(A) a pharmaceutically effective amount of the pharmacologically active agent, and(B) an optically active or inactive pyroglutamate of the following formula ##STR1## wherein R represents a linear, branched or cyclic alkyl or alkenyl group having 10 to 14 carbon atoms,as a penentration enhancer.

Abstract: A sustained release preparation comprising:(a) a non-anionic cellulose ether(b) a methoxyethylene-maleic anhydride copolymer or the hydrolyzate thereof, and(c) pharmaceutically active agents.This sustained release preparation can provide the desired sustained-release or dissolution of the pharmaceutically active agents in human organs irrespective of the acidity (i.e., pH conditions) therein.